CA6 Antibody

What is CA6 and what types of CA6 antibodies are studied in research?

CA6 refers to two distinct entities in scientific research:

Carbonic Anhydrase 6 (CA6): A zinc-containing secreted protein specifically expressed in salivary glands that catalyzes the hydration of carbon hydroxide in saliva. CA6 is also known as gustin and plays a role in pH regulation and electrolyte balance. The amino acid sequence is highly conserved across species. Decreased CA6 protein has been associated with loss of taste and pathological morphology of taste buds .

Coxsackievirus A6 (CA6): One of the major causative agents of herpangina and hand-foot-mouth disease (HFMD). Since 2008, CA6 has circulated widely around the world, particularly in the Asia-Pacific region where it replaced enterovirus A71 (EV71) and coxsackievirus A16 (CA16) as the main prevalent strain of HFMD .

Research on CA6 antibodies generally focuses on:

• Autoantibodies against Carbonic Anhydrase 6 in autoimmune conditions

• Neutralizing antibodies against Coxsackievirus A6 for vaccine development

• Antibodies developed as research tools or therapeutic agents

How are anti-CA6 autoantibodies detected in laboratory settings?

The primary method for detecting anti-CA6 autoantibodies is Enzyme-Linked Immunosorbent Assay (ELISA):

ELISA Protocol for Anti-CA6 Detection:

• Serum samples are typically diluted 100 times according to ELISA kit instructions

• Saliva samples may be diluted 10 times based on pilot experiments

• Results are expressed in ELISA units per milliliter (EU/ml)

• A value ≥ 20 EU/ml is generally defined as positive

• Antibody isotypes (IgG, IgA, IgM) are usually tested separately

For research involving clinical samples, positivity is often defined as at least one of the IgG, IgM, or IgA isotypes being ≥ 20 EU/ml. Some studies also use indirect immunofluorescence or cell-based immunofluorescence cytochemistry as alternative detection methods .

In contrast, neutralizing antibodies against Coxsackievirus A6 are typically measured using the microcytopathic method, which is recognized as the gold standard for enterovirus neutralizing antibody detection .

What is the significance of different isotypes of anti-CA6 autoantibodies in Sjögren's syndrome research?

The different isotypes of anti-CA6 autoantibodies (IgG, IgA, IgM) demonstrate varying patterns of expression and clinical correlations in Sjögren's syndrome (SS):

Research has shown that:

• In a study of patients with long-standing SS, 38% had IgA anti-CA6 antibodies, while only 7% had IgA anti-PSP and 9% had IgA anti-SP1 .

• In a population of dry eye patients, CA6 IgG was the marker most commonly elevated (25.0%), followed by CA6 IgM (22.7%) :

• Anti-CA6-positive patients have significantly higher levels of serum IgA, suggesting a potential relationship between mucosal immunity and CA6 autoimmunity .

How do anti-CA6, anti-SP1, and anti-PSP antibodies compare to traditional biomarkers (anti-Ro/SSA and anti-La/SSB) in Sjögren's syndrome diagnosis?

These tissue-specific autoantibodies (TSAs) offer several advantages as diagnostic biomarkers compared to traditional markers:

• Temporal expression: Anti-CA6, anti-SP1, and anti-PSP appear earlier in disease progression than anti-Ro/SSA and anti-La/SSB antibodies. In patients with less than 2 years of sicca symptoms, 76% had anti-SP1 or anti-CA6 antibodies, while only 31% had anti-Ro or anti-La .

• Tissue specificity: CA6, SP1, and PSP are specific to salivary and lacrimal glands, while Ro and La antigens are found in virtually all cells of the body, making TSAs potentially more specific markers for Sjögren's syndrome .

• Complementary diagnostic value: The positivity of anti-CA6, anti-PSP, and all three TSAs together is significantly increased in anti-SSA-negative SS patients, potentially helping to identify patients who would be missed by traditional testing :

• Correlation with symptoms: Research suggests that CA6 antibodies have the strongest association with ocular sicca symptoms among the TSAs .

• Presence in seronegative patients: In patients diagnosed with Sjögren's but lacking anti-Ro and anti-La antibodies, 45% had anti-SP1 antibodies and 5% had anti-CA6 antibodies .

What methodological approaches are used to develop and validate immuno-PET tracers targeting CA6?

The development of immuno-PET tracers targeting CA6 involves several methodological steps:

• Antibody fragment engineering:

  • Antibody fragments (Fab, diabody) are derived from CA6-targeting antibodies such as huDS6

  • Construction involves using light variable domain (VL) and heavy variable domain (VH) sequences

  • Different formats may be constructed, including B-Fab, CODV-Fab, and diabody configurations

• Radiolabeling strategy:

  • Copper-64 (64Cu) with half-life of 12.7 hours is used for radiolabeling

  • DOTA is employed as a chelator for stable copper binding

  • The radiolabeled complex [64Cu]-DOTA-BFab is assessed for stability

• In vitro validation:

  • Immunoreactivity testing (>70% is considered acceptable)

  • Stability testing in human serum (>95% stability after 24 hours)

  • CA6 binding specificity assessment using CA6-positive and CA6-negative cell lines

• Preclinical evaluation:

  • Testing in tumor-bearing mouse models

  • Comparing uptake between CA6-positive and CA6-negative tumors

  • Assessing tumor-to-background ratios and clearance kinetics

• Clinical translation:

  • Safety and tolerability studies in patients

  • Comparison with conventional imaging ([18F]FDG PET/CT)

  • Correlation with CA6 expression determined by immunohistochemistry

Preclinical results showed that the [64Cu]BFab tracer demonstrated 1.6-fold higher uptake in CA6-positive tumors compared to CA6-negative tumors at 24 hours post-injection, with faster clearance from non-tumor tissues compared to full-length antibodies .

How are CA6 neutralizing antibody standards established for research and vaccine development?

The establishment of standards for CA6 (Coxsackievirus A6) neutralizing antibodies involves a systematic process to ensure reliability and comparability across research settings and vaccine development:

• Production of candidate standards:

  • Selection of plasma samples from healthy individuals with neutralizing activity

  • Lyophilization of samples (typically 0.40 ml/vial)

  • Production of multiple candidate standards with varying antibody titers

• Collaborative study design:

  • Organization by national regulatory authorities (e.g., National Institutes for Food and Drug Control)

  • Participation of multiple laboratories with experience in CA6-related research

  • Standardized testing protocols for comparison

• Assessment criteria:

  • Ability to minimize variability in neutralization titers between laboratories

  • Effectiveness across challenging viruses of different genotypes (e.g., A, D1, D3)

  • Long-term stability evaluation

• Standardization process:

  • Selection of the optimal candidate based on performance

  • Assignment of potency in units per milliliter (U/ml)

  • Formal establishment as a national or international standard

In the case of the first Chinese national standard for CA6 neutralizing antibody, three lyophilized candidate standards (29#, 39#, and 44#) were evaluated, with the 29# candidate selected as the standard and assigned a potency of 150 units per milliliter (U/ml) .

This standardization is critical because:

• It ensures accuracy of neutralizing antibody tests

• It enables reliable comparison of results between different laboratories

• It supports quality control in vaccine development and evaluation

• It facilitates regulatory approval processes for vaccines and therapeutic antibodies

What are the methodological challenges in detecting and interpreting anti-CA6 antibodies in ethnically diverse populations?

Research on anti-CA6 antibodies faces several methodological challenges when applied to diverse populations:

• Ethnic variations in antibody prevalence and expression:

  • Studies have identified that 41% of early Sjögren's markers (EMS)-positive individuals were Hispanic or Latino

  • Limited published data exists about multi-ethnic US populations with Sjögren's syndrome

  • French studies found that anti-SSA/SSB antibody positivity was more frequent in subjects of non-European background

  • New York studies found higher incidence of Sjögren's in Asians compared to Latinos

• Standardization of detection methods:

  • Variability in ELISA kit sensitivity and specificity across laboratories

  • Differences in threshold values for positivity

  • Need for population-specific reference ranges

• Confounding factors affecting interpretation:

  • Environmental factors that may influence autoantibody development

  • Variations in genetic background affecting antibody production

  • Comorbid conditions that may alter antibody profiles

• Sampling limitations:

  • Most studies on anti-CA6 antibodies have been limited to cohorts of 150 patients or less

  • Need for larger, ethnically diverse populations to validate findings

  • Geographic variations in exposure to potential triggering factors

• Validation requirements:

  • Need for comparative analysis between different ethnic groups

  • Importance of correlating antibody findings with clinical presentations

  • Necessity of longitudinal studies to understand antibody dynamics in different populations

Research suggests that anti-CA6 antibodies may have different implications in different ethnic groups, highlighting the need for studies that specifically address ethnic diversity in antibody expression and disease manifestation.

What is the relationship between anti-CA6 antibodies and clinical manifestations in patients with dry eye and Sjögren's syndrome?

The relationship between anti-CA6 antibodies and clinical manifestations shows several noteworthy patterns:

Research suggests that anti-CA6 antibodies may represent both markers of disease and potentially contribute to pathogenesis through direct effects on salivary gland function, though more research is needed to fully characterize these relationships.

How can researchers select the most appropriate CA6 antibody format for specific experimental applications?

Selecting the optimal CA6 antibody format requires consideration of several factors based on the specific research application:

• Experimental purpose and target accessibility:

  • Full-length antibodies (IgG): Provide high avidity and long half-life, suitable for applications requiring extended circulation or effector functions

  • Fab fragments: Smaller size (~50-55 kDa) allows better tissue penetration but with shorter half-life

  • BFab format: Demonstrated high binding affinity and stability with faster clearance than full antibodies

  • Diabody format: Intermediate size with bivalent binding capability

• Imaging applications:

  • For immuno-PET, the BFab format showed promising ability to differentiate between CA6-positive and CA6-negative tumors as early as 6 hours post-injection

  • [64Cu]-DOTA-BFab demonstrated >95% stability after 24 hours in human serum and immunoreactivity of >70%

  • For early imaging time points (6-24 hours), antibody fragments are preferred over full-length antibodies due to faster clearance

• Epitope targeting:

  • C-terminal region targeting: For example, the rabbit anti-human CA6 (C-term) antibody targets a synthetic peptide between 279-308 amino acids from the C-terminal region

  • Consider epitope conservation across species if cross-reactivity is desired

• Detection method compatibility:

  • Western Blotting: Polyclonal antibodies targeting specific regions like the C-terminus of CA6

  • Immunohistochemistry: Validated antibodies with demonstrated specificity in fixed tissues

  • Flow cytometry: Antibodies with proven performance in detecting native proteins on cell surfaces

• Host species and isotype considerations:

  • Mouse monoclonal IgM antibodies show different tissue distribution compared to rabbit polyclonal IgG

  • Host species should be considered to avoid cross-reactivity in multi-color experiments

  • Isotype selection impacts secondary detection systems and potential background

When studying anti-CA6 autoantibodies in patient samples, researchers should specifically test for IgG, IgA, and IgM isotypes separately, as each offers different diagnostic and research value in conditions like Sjögren's syndrome.

What are the latest developments in using CA6 antibodies as companion diagnostics for antibody-drug conjugate therapy?

Recent research has focused on developing CA6 antibodies as companion diagnostics for antibody-drug conjugate (ADC) therapy, particularly for cancers expressing the CA6 antigen:

• Development of antibody fragments for immuno-PET:

  • An antigen binding fragment (BFab) derived from a tumor-associated mucin 1-sialoglycotope antigen (CA6) targeting antibody (huDS6) has been engineered

  • This fragment was radiolabeled with copper-64 [64Cu] to create an immunoPET tracer

  • The tracer enables global assessment of antigen expression, biodistribution, pharmacokinetics, and clearance to predict ADC treatment responses

• Target selection rationale:

  • The CA6 epitope is found on various solid tumors (breast, ovarian, cervical, lung, and pancreatic tumors)

  • It has limited expression in normal adult tissues, creating an ideal antigen for patient stratification

  • The carbonic anhydrase 6 epitope is homogeneous in 96% of breast and ovarian cancers

• Companion diagnostic applications:

  • The [64Cu]BFab tracer serves as a companion diagnostic to the ADC SAR566658 (huDS6-DM4)

  • The ADC targets the CA6 antigen and is conjugated to the cytotoxic maytansinoid derivative DM4

  • Upon binding and internalization, DM4 is released and disrupts microtubule assembly/disassembly dynamics, causing mitotic arrest in CA6-expressing tumor cells

• Preclinical and clinical validation:

  • The BFab construct demonstrated improved tumor uptake at earlier time points compared to full-length antibodies

  • At 24 hours post-injection, the uptake ratio in CA6-positive tumors was 1.6-fold higher than in CA6-negative tumors

  • Initial human studies have investigated the safety and tolerability of [64Cu]BFab and its utility for detecting CA6 expression in cancer patients

This approach represents a significant advance in personalized medicine for cancer treatment, allowing for better patient selection and potentially predicting response to targeted therapy.

How can researchers reconcile contradictory findings about the prevalence and significance of anti-CA6 antibodies across different studies?

Researchers face challenges in reconciling contradictory findings about anti-CA6 antibodies, which require several methodological approaches:

• Standardization of detection methods:

  • Use standardized ELISA kits with established cutoff values

  • Compare results only when using identical detection methods

  • Report detailed methodological parameters to enable proper comparison

• Addressing population heterogeneity:

  • Stratify results by demographic factors (age, sex, ethnicity)

  • Consider disease duration and severity as confounding variables

  • Report detailed cohort characteristics to enable proper comparison

• Isotype-specific analysis:

  • Always analyze IgG, IgA, and IgM isotypes separately

  • Different isotypes show varying patterns in different studies

  • In some cohorts, IgA anti-CA6 antibodies were most significant, while in others, IgG predominated

• Study design considerations:

  • Cross-sectional vs. longitudinal data collection affects interpretation

  • Selection of appropriate control groups is critical

  • Sample size calculations should be based on expected effect sizes

• Meta-analytical approaches:

  • Systematic reviews can help identify patterns across studies

  • Statistical pooling of data when methodologically appropriate

  • Careful evaluation of study quality and risk of bias

• Disease subtype analysis:

  • Primary vs. secondary Sjögren's syndrome may show different antibody profiles

  • Early vs. established disease shows different patterns of antibody expression

  • Patients with overlapping autoimmune conditions may have unique profiles

For example, studies show varying rates of anti-CA6 positivity ranging from 5% to 38% depending on the isotype examined and patient population. These discrepancies might be explained by differences in disease duration, ethnic composition, detection methods, and isotype focus .

What experimental designs are most effective for evaluating the potential of anti-CA6 antibodies as early diagnostic markers in Sjögren's syndrome?

Optimal experimental designs for evaluating anti-CA6 antibodies as early diagnostic markers include:

• Prospective longitudinal cohort studies:

  • Enroll individuals with early sicca symptoms but without established diagnosis

  • Collect baseline samples and clinical data, with regular follow-up over 5+ years

  • Track progression from sicca symptoms to established Sjögren's syndrome

  • Correlate initial anti-CA6 status with disease development

• Nested case-control studies within large biobanks:

  • Identify cases that developed Sjögren's syndrome during follow-up

  • Select appropriately matched controls who did not develop disease

  • Test archived samples collected years before diagnosis

  • Evaluate predictive value of early anti-CA6 positivity

• Family-based studies:

  • Include first-degree relatives of Sjögren's syndrome patients

  • Screen for anti-CA6 antibodies and subclinical manifestations

  • Follow relatives longitudinally for disease development

  • Evaluate genetic and environmental interactions

• Comprehensive isotype and subclass analysis:

  • Test all major antibody isotypes (IgG, IgA, IgM)

  • Consider IgG subclasses (IgG1-4) for more detailed characterization

  • Analyze patterns of isotype switching over time

  • Correlate with disease manifestations and progression

• Multi-marker panels and algorithm development:

  • Combine anti-CA6 with other early markers (anti-SP1, anti-PSP)

  • Include traditional markers (anti-Ro/SSA, anti-La/SSB)

  • Develop weighted scoring algorithms

  • Validate in independent cohorts with different ethnic compositions

• Integration with functional measures:

  • Correlate antibody presence with objective measures of glandular function

  • Include sialometry, Schirmer's test, ocular staining scores

  • Assess relationship to histopathological findings

  • Evaluate biological impact through mechanistic studies

Studies should include adequate sample sizes, with power calculations based on expected prevalence rates (approximately 25-38% for anti-CA6 positivity) and anticipated effect sizes for predicting disease progression .

What are the optimal storage and handling conditions for maintaining CA6 antibody activity in research applications?

Proper storage and handling of CA6 antibodies is crucial for maintaining their activity and reliability in research applications:

• Temperature conditions:

  • Long-term storage: -20°C or -80°C (preferred for some preparations)

  • Short-term storage (1-2 weeks): 2-8°C

  • Commercial antibodies like Rabbit Anti-Human CA6 (C-term) Antibody should be stored at -20°C for long-term preservation

• Solution formulation:

  • Many CA6 antibodies are provided in phosphate-buffered saline (PBS)

  • Some preparations include stabilizers like glycerol, BSA, or sodium azide

  • The 66909-1-PBS CA6 antibody is provided in PBS only

• Aliquoting recommendations:

  • Divide antibodies into small, single-use aliquots upon receipt

  • Minimize freeze-thaw cycles (typically limit to <5 cycles)

  • Use sterile technique when handling to prevent contamination

• Stability considerations:

  • The Chinese national standard for CA6 neutralizing antibody (29# candidate) demonstrated good long-term stability in lyophilized form

  • Reconstituted antibodies typically have limited stability at working concentrations

• Shipping and temporary storage:

  • Many CA6 antibodies are shipped on blue ice

  • Upon receipt, transfer immediately to recommended storage conditions

  • Avoid prolonged exposure to room temperature

• Quality control measures:

  • Periodically test antibody activity using positive controls

  • Monitor for signs of degradation (precipitation, loss of specificity)

  • Note lot-to-lot variations that may affect experimental reproducibility

For recombinant antibody fragments like BFab and diabody constructs, specific handling instructions may apply based on their particular formulation and stability characteristics .

How can researchers validate the specificity of anti-CA6 antibodies in their experimental systems?

Validation of anti-CA6 antibody specificity requires a systematic approach using multiple complementary methods:

• Positive and negative control samples:

  • Use cell lines or tissues with known CA6 expression status

  • Include CA6 knockout/knockdown samples as negative controls

  • Test samples from multiple species if cross-reactivity is claimed

• Blocking experiments:

  • Pre-incubate antibody with purified CA6 antigen

  • Compare staining/binding with and without blocking

  • Specific binding should be significantly reduced or eliminated after blocking

• Isotype control experiments:

  • Use matched isotype control antibodies (e.g., irrelevant IgG or IgM)

  • Apply at the same concentration as the test antibody

  • Compare patterns to identify non-specific binding

• Multiple detection methods:

  • Validate across different techniques (Western blot, IHC, flow cytometry)

  • Each method provides different information about specificity

  • For example, the CA6 Antibody (C-term) has been validated in Western blot, IHC-P, and flow cytometry

• Epitope mapping:

  • Determine the specific region recognized by the antibody

  • Use peptide arrays or deletion mutants

  • Confirm binding to the expected epitope (e.g., C-terminal region between 279-308 amino acids for some anti-CA6 antibodies)

• Antibody titration:

  • Test across a range of concentrations to determine optimal working dilution

  • Evaluate signal-to-noise ratio at each concentration

  • Document lot-specific optimal concentrations

• Cross-validation with different antibody clones:

  • Compare results using antibodies targeting different epitopes

  • Concordant results from multiple antibodies increase confidence in specificity

  • Discrepancies should be investigated to determine the cause

Researchers should document their validation methods thoroughly and include appropriate controls in all experiments to demonstrate antibody specificity.

What emerging technologies might enhance the detection and characterization of CA6 antibodies in research and clinical settings?

Several emerging technologies show promise for advancing CA6 antibody research:

• Single B-cell antibody sequencing:

  • Isolation of CA6-specific B cells from patients

  • Sequencing of paired heavy and light chain genes

  • Expression of recombinant antibodies for functional characterization

  • Provides insights into the development of CA6 autoimmunity

• Mass cytometry and spectral flow cytometry:

  • Simultaneous detection of multiple cellular parameters

  • Characterization of B cells producing anti-CA6 antibodies

  • Correlation with other immune markers

  • High-dimensional analysis of immune signatures

• Advanced imaging techniques:

  • Beyond [64Cu]BFab, newer PET radiotracers with improved properties

  • Multimodal imaging combining PET with MRI or optical imaging

  • Intraoperative imaging using fluorescently labeled anti-CA6 antibodies

  • Higher resolution imaging of CA6 expression in tissues

• Microfluidic and digital ELISA platforms:

  • Increased sensitivity for detecting low-abundance antibodies

  • Reduced sample volume requirements

  • Automated high-throughput screening

  • Improved quantification and reproducibility

• Machine learning algorithms:

  • Pattern recognition in complex antibody datasets

  • Integration of multiple autoantibody measurements

  • Prediction of disease progression based on antibody profiles

  • Personalized risk assessment tools

• Glycoproteomic analysis:

  • Characterization of glycosylation patterns on anti-CA6 antibodies

  • Correlation with antibody function and pathogenicity

  • Identification of disease-specific glycoforms

  • New biomarkers based on antibody glycosylation

• Portable point-of-care testing:

  • Rapid detection of anti-CA6 antibodies in clinical settings

  • Field-applicable technologies for epidemiological studies

  • Smartphone-based readers for semi-quantitative results

  • Integration with electronic health records

These technologies could significantly enhance our ability to detect, characterize, and interpret CA6 antibodies in both research and clinical contexts, potentially leading to earlier diagnosis and more personalized treatment approaches.